ETH-LAD

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
ETH-LAD
ETH-LAD structure.png
Clinical data
Synonyms ETH-LAD, 6-ethyl-6-nor-Lysergic acid diethylamide
Routes of
administration
Oral
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic
Excretion Renal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C21H27N3O
Molar mass 337.47 g/mol
3D model (JSmol)
 NoYesY (what is this?)  (verify)

ETH-LAD, 6-ethyl-6-nor-lysergic acid diethylamide is an analogue of LSD. Its human psychopharmacology was first described by Alexander Shulgin in the book TiHKAL. ETH-LAD is a psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[1] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding.

Legality[edit]

On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[2] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.

ETH-LAD is illegal in Switzerland as of December 2015.[3]

Literature[edit]

  • Andrew J. Hoffman, David E. Nichols: Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. In: Journal of Medicinal Chemistry. 28, 1985, p. 1252–1255, doi:10.1021/jm00147a022.
  • V. J. Watts, R. B. Mailman, C. P. Lawler, K. A. Neve, D. E. Nichols: LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. In: Psychopharmacology. 118, 1995, p. 401–409, doi:10.1007/BF02245940.
  • T. Niwaguchi, Y. Nakahara, H. Ishii: Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. In: Yakugaku Zasshi. Vol. 96, No. 5, May 1976, p. 673–678, PMID 987200.
  • Robert C. Pfaff, Xuemei Huang, Danuta Marona-Lewicka, Robert Oberlender and David E. Nichols: Lysergamides Revisited. In: NIDA Research Monograph 146: Hallucinogens: An Update. p. 52, 1994, United States Department of Health and Human Services.
  • Simon D. Brandt, Pierce V. Kavanagh et al.: Return of the lysergamides. Part III: Analytical characterization of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). In: Drug Testing and Analysis. 2017, doi:10.1002/dta.2196.

See also[edit]

References[edit]

  1. ^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428. 
  2. ^ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014. 
  3. ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat. 

External links[edit]